Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis
Data presented at key congresses in North America and Europe
Cambridge, UK – 21 February 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held February 18-21 in Banff, Canada and at the European Crohn’s and Colitis Organisation (ECCO) meeting held February 19-22 in Berlin.
MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC patients, without immunosuppression or unwanted side effects.
Data from new preclinical studies presented at the congresses demonstrated that MB310 acts via at least three independent mechanisms of action (MOA) that are central to the pathology of UC: promoting the healing of the damaged gut epithelial barrier, regulating the balance of cytokines that are inflammatory (TNF) and immune-modulatory (IL-10); and inducing a regulatory T-cell response. This included novel data demonstrating that different strains induce regulatory T-cells by different mechanisms. MB310 is in a Phase 1 study COMPOSER-1, with data readout expected by the end of 2025.
At the ECCO meeting Dr Fernanda Schreiber, Associate Director of Translational Biology, will present ‘Mechanistic understanding of MB310: a consortium of gut commensal bacteria for the treatment of ulcerative colitis’. The poster can be accessed here (https://microbiotica.com/2025-ecco-poster).
At the Keystone meeting, Microbiotica’s Senior Vice President of Research, Dr Mat Robinson, presented a poster entitled ‘Mechanistic understanding of eight commensal gut bacteria associated with clinical remission in ulcerative colitis patients’. The poster can be accessed here (https://microbiotica.com/2025-keystone-poster).
In addition, the Company’s Chief Scientific Officer and co-founder, Dr Trevor Lawley, delivered a presentation at the Keystone meeting on ‘Integrating Mass Culturing and Metagenomic Analysis for Human Microbiome Translational Science’. In this session Trevor drew on his experience as a Senior Group Leader at the Wellcome Sanger Institute combined with his CSO role at Microbiotica.
